So Hyun Bae Tae Wan Kim Hum Chung Jang Won Heo
10.3341/kjo.2013.27.1.61
Korean J Ophthalmol
2013 Feb;27(1):61-3.
bevacizumab cytomegalovirus retinitis
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/23372384/
Antibodies, Monoclonal, Humanized / adverse effects Cytomegalovirus Retinitis / etiology Immunocompetence / drug effects Macular Edema / drug therapy
Antibodies, Monoclonal, Humanized / adverse effects Cytomegalovirus Retinitis / etiology Immunocompetence / drug effects Macular Edema / drug therapy Case Reports Angiogenesis Inhibitors / administration & dosage Angiogenesis Inhibitors / adverse effects Antibodies, Monoclonal, Humanized / administration & dosage Bevacizumab Cytomegalovirus / genetics Cytomegalovirus Retinitis / diagnosis Cytomegalovirus Retinitis / immunology DNA, Viral / analysis Diagnosis, Differential Female Humans Intravitreal Injections Macular Edema / diagnosis Middle Aged Polymerase Chain Reaction Vascular Endothelial Growth Factor A / antagonists & inhibitors Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized DNA, Viral Vascular Endothelial Growth Factor A Bevacizumab
PMC3550316
23372384
Cytomegalovirus retinitis after intravitreal bevacizumab injection in an immunocompetent patient
2013